Skip to main content
. 2022 May 2;2(5):277–285. doi: 10.1158/2767-9764.CRC-21-0156

FIGURE 2.

FIGURE 2

NGS of the ALK-expressing tumor reveals a novel oncogenic SLC45A3-ALK rearrangement. A, Schematic showing the fusion transcript involving noncoding exon 1 of SLC45A3 (break point hg19 chr1:205634335) and exon 16 of ALK (break point hg19 chr2:29452318). B, Overexpression of the fusion transcript comprising ALK exons 16–29 (ALK16–29) in hTERT immortalized benign prostate epithelial cells (hTERT-PrEC) resulted in significantly increased cell proliferation which was reduced by treatment with the ALK inhibitor crizotinib (crizo).